The Food and Drug Administration (FDA) may approve the first long-acting therapy for HIV pre-exposure prophylaxis (PrEP) within the next few months.On Tuesday, the pharmaceutical company ViiV Healthcare announced that the FDA has accepted and granted priority review for a new drug application (NDA) for cabotegravir, an injectable form of PrEP administered every two months.
The FDA’s target approval date is Jan. 24, 2022.Created in 2009 by Pfizer and GlaxoSmithKline, ViiV Healthcare specializes in HIV treatment and prevention.The NDA was based on the results of two double-blind studies that evaluated the safety and efficacy of cabotegravir.
Read more on metroweekly.com
Get the latest stars news and celebrity rumours with exclusive stories, photos, videos and interviews.
Breaking up, scandals, engagements, divorces, gossip – all you need to know about the private lives of your favorite celebs.
Get to know the latest showbiz news along with exclusive interviews and even more. All this is waiting for you on the main page 24 hours a day, 7 days a week! Who, where, when, with whom, how, why and for what!? Stay tuned to know first!
Just follow us daily and we will provide you with the current news from the life of famous stars and celebrities.
Owner: SNOWLAND s.r.o.
Registration certificate 06691200
Address:
Snowland s.r.o.
16200, Na okraji 381/41, Veleslavín, 162 00 Praha 6
Czech Republic
©2024. All rights reserved.